Clinical trials
Advanced Solid Tumor Cancer clinical trials
Below are recruiting advanced solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,352 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT04299191RecruitingPhase 1/Phase 2
LAM561 for children with advanced brain or solid tumors
This Phase 1/2 study tests a medicine called LAM561 in children whose cancer is advanced and not responding to standard treatment. The goal is to see if the drug is safe and can shrink or control tumors in this setting.
Little Rock, ArkansasAges Up to 18 years - NCT04370587RecruitingPhase 1/Phase 2
Injecting a cancer medicine into tumors plus pembrolizumab
This Phase 1/2 study tests a medicine injected directly into a tumor, alone or with pembrolizumab (an immune-therapy drug given through a vein). It is for people with advanced or metastatic solid cancers that have grown despite standard treatments, aiming to improve tumor control.
Gilbert, ArizonaAges 18 years+ - NCT04389281RecruitingPhase 1
X-ray light-activated therapy for hard-to-treat skin tumors
This early-phase study tests an X-ray–activated medicine that is delivered directly into selected tumors to help control cancer that has not responded to standard treatments. If the injected area can be treated safely, it may shrink or slow the tumor and improve local control.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04443088RecruitingPhase 1
Study drug INV-1120 with or without pembrolizumab for advanced cancers
This Phase 1 trial studies INV-1120 alone and with pembrolizumab (an immune therapy) in adults with advanced solid tumors that have stopped responding to standard treatment or have no standard option. The goal is to see how the treatments work, what dose is safest, and what side effects may occur.
Lafayette, IndianaAges 18 years+ - NCT04471987RecruitingPhase 1
IL-12 drug for metastatic cancer after checkpoint therapy
This Phase 1 trial studies the safety of an investigational drug called IL-12-L19L19 and looks for early signs it may help control advanced (metastatic) solid tumors. It is designed for people whose cancer has continued to grow even after treatment with immune “checkpoint” therapies.
Hamburg, Free and Hanseatic City of HamburgAges 18–80 - NCT04495790Recruiting
Cancer patient study to track health outcomes
This is an observational study that follows people with cancer to better understand outcomes over time. You may be asked to complete questionnaires and share information from your visits (in person or by video only if you meet their rules).
Seattle, WashingtonAges Any age - NCT04516447RecruitingPhase 1
Testing a new drug for advanced ovarian cancer
This Phase 1 trial studies how well and how safely azenosertib (ZN-c3) works in people with advanced ovarian, fallopian tube, or peritoneal cancer. It may help by offering a new treatment option for cancers that don’t respond well to platinum chemotherapy (platinum-resistant).
Aurora, ColoradoAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Study drug for TP53 Y220C-mutated advanced cancers
This early-phase study tests PC14586 (rezatapopt) in people with advanced or metastatic solid cancers that carry a specific TP53 mutation called Y220C. It mainly looks at safety and how well the treatment may work, sometimes combined with pembrolizumab.
Irvine, CaliforniaAges 12 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT04771520RecruitingPhase 2
Avapritinib for tumors with specific KIT or PDGFRA changes
This Phase 2 trial studies avapritinib, a targeted medicine, for people whose cancer has specific KIT or PDGFRA genetic changes. It may help shrink or slow growth of certain advanced cancers, including some brain tumors, when standard treatments have not worked or for specific glioblastoma cases.
Houston, TexasAges 18 years+ - NCT04777994RecruitingPhase 1
Drug ABBV-CLS-484 for advanced cancers that lack options
This Phase 1 trial tests ABBV-CLS-484 in people with advanced or metastatic tumors when standard treatments have not worked or aren’t available. Because it’s an early study, the main goal is to find a safe dose and see how the cancer responds in different cancer types.
Tucson, ArizonaAges 18 years+ - NCT04778839RecruitingPhase 1
Paclitaxel drug in tiny “micelles” for advanced solid cancers
This Phase 1 trial tests a chemotherapy drug called paclitaxel in a special “micelle” form in people with advanced solid tumors. It’s mainly designed to check safety and dosing, and it may help shrink tumors in people who don’t have good standard treatment options.
Hanzhou, ZhejiangAges 18–70 - NCT04827810RecruitingPhase 1
IV gamitrinib study for advanced cancers needing new options
This early-phase trial tests how safe IV gamitrinib is and how the body processes it in people with advanced cancers that can’t be controlled by standard treatment. It may also help researchers learn the best dose and whether it has signs of anti-cancer activity.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04842812RecruitingPhase 1
Personalized immune cell therapy for advanced solid tumors
This Phase 1 study tests engineered immune cells (TILs/CAR-TILs) made from your tumor to treat advanced solid cancers that have not responded to standard treatments. It may help your immune system better recognize and attack the cancer, but it is mainly focused on safety and early results.
GuangzhouAges 18–85 - NCT04855435RecruitingPhase 1
Study drug for advanced melanoma and other solid tumors
This Phase 1 trial studies a new experimental immunotherapy (MBS8) for people with advanced solid tumors, focusing first on safety and early signs of benefit. Depending on your cancer type and past treatments, you may receive MBS8 alone or combined with pembrolizumab.
HerlevAges 18 years+ - NCT04872166RecruitingPhase 1
BTX-A51 for advanced solid tumors and breast cancer patients
This Phase 1 study tests BTX-A51, an experimental treatment, in people with advanced cancers that can’t be cured with standard options. It mainly focuses on safety, side effects, and whether the drug can start helping certain tumors.
Lake Mary, FloridaAges 18 years+ - NCT04895709RecruitingPhase 1/Phase 2
Testing a new cancer drug for advanced solid tumors
This early-phase trial tests how well a new drug (BMS-986340) works alone and combined with other treatments in people with advanced solid tumors that have progressed despite standard care. It also studies tumor samples to look for biomarkers that may predict who benefits.
Clovis, CaliforniaAges 18 years+ - NCT04900818RecruitingPhase 1
Givastomig for advanced solid cancers, including gastric and pancreas
This Phase 1 trial tests how safe and effective givastomig (TJ033721) is for advanced or metastatic solid tumors. It may help people whose cancer has grown despite standard treatment, or—if in the combination parts—specific cancers that meet certain lab test and tumor-marker requirements.
Orange, CaliforniaAges 18 years+ - NCT04924075RecruitingPhase 2
Belzutifan for cancers linked to VHL or HIF-2α changes
This Phase 2 study tests belzutifan (MK-6482) to treat certain advanced cancers caused by specific gene or disease changes, including VHL-related tumors and HIF-2α related tumors. It may help shrink tumors or slow their growth in people whose cancer matches these genetic or disease patterns.
Los Angeles, CaliforniaAges 12 years+ - NCT04930432RecruitingPhase 1/Phase 2
MCLA-129 for advanced EGFR- and MET-positive lung and other cancers
This early-phase trial tests MCLA-129, an antibody that targets EGFR and MET, in people with advanced cancers that have specific lab “biomarker” results. It’s for patients whose cancer has grown after standard treatments or can’t take standard treatment, with the goal of shrinking tumors and improving symptoms.
BaodingAges 18 years+ - NCT06889610RecruitingPhase 2
Ablation plus drug therapy for advanced solid tumors
This trial tests combining a liver tumor ablation procedure with systemic drugs for people with advanced colorectal, breast, or melanoma cancer that has spread to the liver. The goal is to see if this approach can help when standard treatments have stopped working.
ShanghaiAges 18–80
Hear when a new Advanced Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced solid tumor cancer?
- Yes. Clin2 currently lists 1,352 recruiting advanced solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.